An announcement from Innovent Biologics ( (HK:1801) ) is now available.
Innovent Biologics has announced the approval of SYCUME®, China’s first IGF-1R monoclonal antibody, by the National Medical Products Administration for treating thyroid eye disease (TED). This approval marks a significant milestone as SYCUME® is the second IGF-1R antibody drug approved globally and offers a new treatment option for TED, which has lacked new therapies for 70 years in China. The drug demonstrated robust efficacy and safety in clinical trials, offering significant clinical and societal value by improving patient outcomes and redefining the standard of care for TED.
More about Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative therapies. The company specializes in biologics, particularly monoclonal antibodies, targeting significant medical needs in China and potentially worldwide.
YTD Price Performance: 10.48%
Average Trading Volume: 38,017
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.2B
For detailed information about 1801 stock, go to TipRanks’ Stock Analysis page.